{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:58:41Z","timestamp":1790459921972,"version":"4.1.0"},"reference-count":18,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:p>In the UK, around 75% of women of reproductive age use some form of contraception.1 Although combined oral contraceptives and barrier contraception are the most widely used, their effectiveness is dependent on their correct and consistent use. In contrast, long-acting reversible contraceptives provide effective and reliable methods of contraception that are not reliant upon user adherence.2 \u25bcJaydess (Bayer) is a new long-acting reversible levonorgestrel-releasing intra-uterine delivery system (IUS) that provides contraception for up to 3 years.3 It was launched in April 2014, and is the second levonorgestrel IUS available in the UK. Here we discuss the evidence for its effectiveness and safety, and consider its place in therapy.<\/jats:p>","DOI":"10.1136\/dtb.2015.1.0304","type":"journal-article","created":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T05:44:44Z","timestamp":1421300684000},"page":"9-12","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["\u25bcJaydess IUS"],"prefix":"10.1136","volume":"53","member":"239","published-online":{"date-parts":[[2015,1,15]]},"reference":[{"key":"2025082623244652000_53.1.9.1","unstructured":"Office for National Statistics, 2009. Opinions Survey Report No 41: contraception and sexual health, 2008\/09 [online]. Available: http:\/\/www.ons.gov.uk\/ons\/rel\/lifestyles\/contraception-and-sexual-health\/2008-09\/2008-09.pdf [Accessed 17 December 2014]."},{"key":"2025082623244652000_53.1.9.2","unstructured":"National Institute for Health and Care Excellence, 2014. Long-acting reversible contraception (update) (CG30) [online]. Available: www.nice.org.uk\/guidance\/cg30 [Accessed 17 December 2014]."},{"key":"2025082623244652000_53.1.9.3","unstructured":"Jaydess 13.5\u2005mg intrauterine delivery system. Summary of product characteristics, UK. Bayer plc, April 2014."},{"key":"2025082623244652000_53.1.9.4","unstructured":"Mirena. Summary of product characteristics, UK. Bayer plc, June 2013."},{"key":"2025082623244652000_53.1.9.5","unstructured":"Faculty of Sexual & Reproductive Healthcare, 2014. Jaydess\u00ae Levonorgestrel Intrauterine System (LNG-IUS) [online]. Available: http:\/\/www.fsrh.org\/pdfs\/CEUProductReviewJaydess.pdf [Accessed 17 December 2014]."},{"key":"2025082623244652000_53.1.9.6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/AOG.0000000000000019","article-title":"Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial","volume":"122","author":"Nelson","year":"2013","journal-title":"Obstet Gynecol"},{"key":"2025082623244652000_53.1.9.7","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.fertnstert.2011.12.003","article-title":"A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena","volume":"97","author":"Gemzell-Danielsson","year":"2012","journal-title":"Fertil Steril"},{"key":"2025082623244652000_53.1.9.8","unstructured":"Lakemedelsverket Medical Products Agency, 2012. Public assessment report scientific discussion: Jaydess (levonorgestrel) [online]. Available: https:\/\/docetp.mpa.se\/LMF\/Jaydess%20intrauterine%20device%20ENG%20PAR.pdf [Accessed 17 December 2014]."},{"key":"2025082623244652000_53.1.9.9","unstructured":"European Medicines Agency, 2005. Guideline on clinical investigation of steroid contraceptives in women [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003349.pdf [Accessed 17 December 2014]."},{"key":"2025082623244652000_53.1.9.10","unstructured":"Bayer Inc, 2014. Product monograph. Jaydess. Levonorgestrel-releasing intra-uterine system (13.5mg). Progestogen. Submission Control No: 174672 [online]. Available: http:\/\/www.bayer.ca\/files\/JAYDESS-PM-EN.pdf? [Accessed 17 December 2014]."},{"key":"2025082623244652000_53.1.9.11","unstructured":"U.S. Food and Drug Administration, 2013. Clinical review [online]. Available: http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/UCM350706.pdf [Accessed 17 December 2014]."},{"key":"2025082623244652000_53.1.9.12","unstructured":"Faculty of Sexual and Reproductive Healthcare, 2007. Intrauterine contraception. Available: http:\/\/www.fsrh.org\/pdfs\/CEUGuidanceintrauterineContraceptionNov07.pdf [Accessed 17 December 2014]."},{"key":"2025082623244652000_53.1.9.13","unstructured":"U.S. National Institutes of Health, 2014. LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study [online]. Available: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01254292 [Accessed 17 December 2014]."},{"key":"2025082623244652000_53.1.9.14","unstructured":"U.S. National Institutes of Health, 2014. LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study [online]. Available: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01397097 [Accessed 17 December 2014]."},{"key":"2025082623244652000_53.1.9.15","unstructured":"U.S. National Institutes of Health, 2014. European Active Surveillance Study of LCS12 (EURAS_LCS12) [online]. Available: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02146950?term=NCT02146950 rank=1 [Accessed 17 December 2014]."},{"key":"2025082623244652000_53.1.9.16","unstructured":"National Institute for Health and Care Excellence, 2014. Long-acting reversible\u00a0contraception: levonorgestrel 13.5\u2005mg intrauterine delivery system (ESNM41) [online]. Available: http:\/\/www.nice.org.uk\/advice\/esnm41 [Accessed 17 December 2014]."},{"key":"2025082623244652000_53.1.9.17","unstructured":"Scottish Medicines Consortium, 2014. Forthcoming Submission: levonorgestrel intrauterine delivery system (Jaydess) [online]. Available: https:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Forthcoming_Submissions\/levonorgestrel_intrauterine_delivery_system_Jaydess [Accessed 17 December 2014]."},{"key":"2025082623244652000_53.1.9.18","unstructured":"All Wales Medicines Strategy Group, 2014. Levonorgestrel (Jaydess\u00ae) [online]. Available: http:\/\/www.awmsg.org\/awmsgonline\/app\/appraisalinfo\/1158 [Accessed 17 December 2014]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2015.1.0304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:24:58Z","timestamp":1756275898000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2015.1.0304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,1,15]]},"published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1136\/dtb.2015.1.0304"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2015.1.0304","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"value":"0012-6543","type":"print"},{"value":"1755-5248","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}